{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Lymphomas&page=3", "query": { "condition": "Relapsed Lymphomas", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 2067, "total_pages": 207, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Lymphomas&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Lymphomas&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T07:37:32.245Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06708897", "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CLL / SLL", "CLL (Chronic Lymphocytic Leukemia)", "SLL (Small Lymphocytic Lymphoma)", "Marginal Zone Lymphoma(MZL)", "Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia" ], "interventions": [ { "name": "Lonitoclax (ZE50-0134)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lomond Therapeutics Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2025-04-08", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-11-14T07:37:32.245Z", "location_count": 5, "location_summary": "Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06708897" }, { "nct_id": "NCT00996047", "title": "S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "cytogenetic analysis", "type": "GENETIC" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 3341, "start_date": "1991-07", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-11-14T07:37:32.245Z", "location_count": 280, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 182 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00996047" }, { "nct_id": "NCT00003243", "title": "Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "1998-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-03-10", "last_synced_at": "2026-11-14T07:37:32.245Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003243" }, { "nct_id": "NCT03328078", "title": "CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Hematologic Malignancy", "Refractory Hematologic Malignancy", "Relapsed Primary Central Nervous System Lymphoma", "Refractory Primary Central Nervous System Lymphoma" ], "interventions": [ { "name": "Emavusertib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Curis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2017-12-28", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-14T07:37:32.245Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Duarte, California • Santa Monica, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03328078" }, { "nct_id": "NCT04234048", "title": "Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-cell Lymphoma", "Cutaneous/Peripheral T-Cell Lymphoma", "Peripheral T-cell Lymphoma", "Peripheral T-Cell Lymphoma, Not Classified", "Primary Cutaneous T-cell Lymphoma", "Cutaneous T-Cell Lymphoma, Unspecified", "Cutaneous T-cell Lymphoma", "Follicular T-Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Sézary's Disease", "Mycosis Fungoides" ], "interventions": [ { "name": "Fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SciTech Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2023-12-18", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-14T07:37:32.245Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04234048" }, { "nct_id": "NCT02401048", "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "MEDI4736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2015-05", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2019-06-27", "last_synced_at": "2026-11-14T07:37:32.245Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02401048" }, { "nct_id": "NCT04788043", "title": "Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Relapsed Classical Hodgkin Lymphoma", "Refractory Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Magrolimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "PET/CT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Ranjana Advani", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-06-21", "completion_date": "2025-08-29", "has_results": true, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-11-14T07:37:32.245Z", "location_count": 2, "location_summary": "Stanford, California • Boston, Massachusetts", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04788043" }, { "nct_id": "NCT05618925", "title": "Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin's Lymphoma Refractory/Relapsed" ], "interventions": [ { "name": "N803", "type": "DRUG" }, { "name": "CD19t-haNK suspension", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-08-22", "completion_date": "2027-03-15", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-11-14T07:37:32.245Z", "location_count": 2, "location_summary": "Newport Beach, California • Tyler, Texas", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Tyler", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05618925" }, { "nct_id": "NCT01460940", "title": "A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Lymphocyte Depletion Hodgkin Lymphoma", "Adult Lymphocyte Predominant Hodgkin Lymphoma", "Adult Mixed Cellularity Hodgkin Lymphoma", "Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma", "Adult Nodular Sclerosis Hodgkin Lymphoma", "Recurrent Adult Hodgkin Lymphoma" ], "interventions": [ { "name": "panobinostat", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2011-10-13", "completion_date": "2016-11-16", "has_results": true, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-11-14T07:37:32.245Z", "location_count": 2, "location_summary": "St Louis, Missouri • Columbus, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01460940" }, { "nct_id": "NCT00131989", "title": "Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2005-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-09", "last_synced_at": "2026-11-14T07:37:32.245Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00131989" } ] }